News

Preclinical results suggest that delivery of the atonal gene using GenVec’s innovative adenovector technology may have the potential to restore hearing and balance function. As per the agreement,

Pamidronate disodium is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors

Atul Sobti, MD and CEO of Ranbaxy, said: “With an increasing focus on prevention of disease, the importance of the vaccine market has never been greater. This transaction

Walter Weller, president and COO of MedPro, said: “The Insulin Guard meets a significant need in the home healthcare market for a truly passive safety self-injector that can

As per the agreement, Idera is entitled to receive a payment of E3m from Merck. The company is expects to receive the milestone payment during the first quarter

The co-development and commercialisation agreement between Perseid and Astellas was originally entered into by Maxygen and Astellas in September 2008, and assigned to Perseid in September 2009, in

The company claims that the samples will be processed at Interleukin Genetics’ CLIA-certified laboratory in Waltham, MA and will receive royalties and processing fees for each test sold.

The secondary objective of the trial also monitored the injected tumour and other distant tumours for signs of Cavatak activity against actively progressing metastatic melanoma. Injected tumours of

Access has focused its Cobalamin product development program on the oral delivery of insulin and human growth hormone. A new Cobalamin-coated insulin-containing nanoparticle formulation delivered orally, provided a